NCT05384210 is a NA clinical trial of Milnacipran in Fibromyalgia, sponsored by Mansoura University.

Who is sponsoring NCT05384210?

NCT05384210 is sponsored by Mansoura University.

What drugs are being tested in NCT05384210?

Interventions in NCT05384210: Milnacipran, Gabapentin, Combined gabapentin/milnacipran.

What condition does NCT05384210 study?

NCT05384210 studies Fibromyalgia.

Is NCT05384210 still recruiting?

NCT05384210 is currently status unknown. Last updated 17 May 2022.

Last reviewed 2022-05-17 · How we verify

NCT05384210

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Milnacipran Versus Gabapentin or Combination of Both in Fibromyalgia Syndrome

Status unknown NA Last updated 17 May 2022

What this trial tests

NA trial testing Milnacipran in Fibromyalgia in 75 participants. Status unknown.

Timeline

1 June 2022

Primary endpoint
1 October 2023

1 November 2023

Quick facts

Lead sponsor	Mansoura University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	75
Start date	1 June 2022
Primary completion	1 October 2023
Estimated completion	1 November 2023
Sites	1 location across Egypt

Drugs / interventions tested

Milnacipran — full drug profile →
Gabapentin (Gabapentin) — full drug profile →
Combined gabapentin/milnacipran — full drug profile →

Conditions studied

Fibromyalgia — all drugs for Fibromyalgia →

Sponsor

Mansoura University

Who can join

Adults 18 to 70, female only, with Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Visual analogue scale (VAS) for pain
Time frame: 3 months
Assesses the overall pain of fibromyalgia on a 10 cm pain scale with 0 indicating no pain and 10 indicating the worst pain ever

Sponsor's own description

Gabapentin and milnacipran (MLN) show strong evidence of reduced pain, increased sleep, and improvement in the quality of life in fibromyalgia (FM) patients. Most FM trials focus primarily on pain reduction with monotherapy. Polypharmacy is commonly used, but supportive evidence is limited. The gabapentin-MLN combined therapy may be more effective in female patients with FM than their monotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.
Guo X, Liu H, Song YJ, Wang JH, et al · · 2026 · cited 2× · PMID 41583906 · DOI 10.1002/mco2.70497

Verify or expand the search:

Other trials of Milnacipran

Trials testing the same drug.

NCT02783430 — Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease · Phase 2, PHASE3 · completed
NCT01328002 — Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia · Phase 2 · terminated
NCT01288937 — A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain · Phase 3 · terminated

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

NCT02285868 — ATI Evidence-based Guide Investigating Clinical Services · active not recruiting
NCT07245303 — Neural Mechanisms of Light Driven Analgesia · NA · recruiting
NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
NCT07358754 — The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor · recruiting
NCT07465991 — The Effect of Digital Cognitive Behavioural Therapy for Insomnia on Physical Activity in Fibromyalgia · NA · recruiting

Other Mansoura University trials

Trials by the same sponsor.

NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
NCT07534943 — Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Period · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05384210 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mansoura University
Last refreshed: 17 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05384210.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing